Last updated: April 1, 2026
What is the Drug Associated with NDC 45802-0486?
NDC 45802-0486 refers to Humira (adalimumab), a biologic agent used primarily for autoimmune conditions such as rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. It is produced by AbbVie and is one of the top-prescribed biologics globally.
Market Overview
Market Size and Trends
- Global biologics market was valued at approximately $330 billion in 2022. Forecasted to reach $540 billion by 2030, growing at a CAGR of nearly 7.8% (Grand View Research, 2023[1]).
- Humira’s revenue in 2022 was $21.3 billion, constituting roughly 6.5% of global biologics sales, making it the best-selling drug worldwide.
Competitive Landscape
- Key competitors include Enbrel (etanercept), Remicade (infliximab), and Cimzia (certolizumab pegol).
- Patent expiry: The original Humira patent expired in the U.S. in 2023, opening the market for biosimilars.
Biosimilars Impact
- Initial biosimilars launched in 2023 in multiple markets.
- Pricing pressure increased; biosimilar prices are approximately 15-30% lower than branded Humira.
- Several biosimilar entrants are competing in the U.S. and Europe, including Amgen’s Amgevita, Samsung Bioepis's Hadlima, and Pfizer's Abrilada.
Regulatory Landscape
- FDA approval of multiple biosimilars since 2023 reduces prices and increases accessibility.
- Pricing adjustments due to biosimilar competition tend to follow a pattern: initial drop in price (10-20%) upon biosimilar launch, followed by stabilization at a lower price point.
Price Projections
Historical Pricing Trends
| Year |
Humira (per dose) |
Biosimilar (per dose) |
Price Change |
| 2022 |
$1,200 – $1,500 |
N/A |
N/A |
| 2023 |
$1,000 – $1,300 |
$850 – $1,200 |
10-20% reduction |
| 2024 |
$950 – $1,250 |
$700 – $1,000 |
Additional 10-25% |
Prices are approximate and vary by market, insurer negotiations, and dosage form.
Short-to-Medium Term (2024–2026)
- Branded Humira: Price expected to stabilize around $950–$1,000 per dose due to reduced patent exclusivity and biosimilar competition.
- Biosimilars: Average prices projected to range from $700–$900, reflecting incremental price reductions and increased market penetration.
Long-term (2027+)
- Market saturation: Biosimilar market share could reach 70–80%, pressuring prices further.
- Price points: Biosimilar prices may decline 30–40% relative to original, reaching as low as $600–$700 per dose, with some competition possibly driving prices below $600.
Pricing factors influencing future rough estimates:
- Patent litigation outcomes and legal barriers.
- Reimbursement policies and government negotiating power.
- Adoption rates among physicians and patients.
- Insurer formulary preferences and rebate negotiations.
Market Drivers and Risks
Drivers
- Expanding indications increase patient access.
- Biosimilar entry stimulates price competition.
- Growing prevalence of autoimmune diseases.
Risks
- Slower biosimilar adoption due to physician and patient preferences.
- Patent litigation delays.
- Pricing regulations and pressure from healthcare payers.
Strategic Implications
- For manufacturers, early biosimilar launches and aggressive discounting will shape profit margins.
- For investors, monitoring biosimilar market share growth and regulatory developments is key.
- For healthcare systems, increased competition could lower costs but may also impact supply stability.
Key Takeaways
- Humira remains a leading biologic with significant revenue influence.
- The biosimilar market has introduced downward price pressures, with a 15-30% initial reduction.
- Prices are expected to decrease gradually over the next 2–5 years, driven by biosimilar competition and regulatory factors.
- Long-term projections suggest biosimilar prices could stabilize around 40% below original, with further declines possible as market dynamics evolve.
FAQs
1. Will Humira’s price decline continue beyond 2026?
Yes. Biosimilar market penetration and increased competition could push prices lower, especially reaching saturation levels around 2028–2030.
2. How does biosimilar adoption influence market share?
Biosimilars are expected to capture 70–80% of Humira’s market share within 5 years of entry in mature markets, significantly impacting pricing.
3. Are all biosimilars priced equally?
No. Prices vary by manufacturer, market strategy, and negotiations. Typically, the earliest biosimilars tend to be less expensive.
4. What regulatory hurdles could affect future price declines?
Patent litigations and regulatory delays could temporarily stall biosimilar entry, limiting downward price pressure.
5. How do reimbursement policies impact price projections?
Policies favoring biosimilars and encouraging cost containment lead to more aggressive pricing discounts.
References
[1] Grand View Research. (2023). Biologics Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/biologics-market
